Phase II trial of levocetirizine with capecitabine and bevacizumab to overcome the resistance of antiangiogenic therapies in refractory metastatic colorectal cancer

BACKGROUND: Despite the clinical success of vascular endothelial growth factor (VEGF) blockade in metastatic colorectal cancers (mCRC), resistance to anti-angiogenic drugs invariably develops. IL-8 and other cytokines have been implicated in development of resistance to anti-angiogenic therapy. Levo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Gastrointest Oncol
Main Authors: Amin, Manik, Desai, Monica, Trinkaus, Kathryn, Brown, Amberly, Wang-Gillam, Andrea, Tan, Benjamin, Picus, Joel, Sorscher, Steven, Highkin, Maureen, Lears, Kim, Lockhart, Albert C.
Formato: Artigo
Idioma:Inglês
Publicado em: AME Publishing Company 2019
Assuntos:
Clinical Trial
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6534727/
https://ncbi.nlm.nih.gov/pubmed/31183190
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2019.02.01
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados